ArticleAAPS PharmSciTech2025
Nano-Engineered Hybridized Polymeric Framework for Chronic Wound Management.
Article in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic wounds, particularly those associated with diabetes, pose a significant challenge in medical care due to their persistent non-healing nature; it is estimated that by 2030, nearly 550 million individuals will be diagnosed with diabetes in the world. This study presents the design and fabrication of a nano-engineered hybridized polymeric framework aimed at enhancing chronic wound management. The designed scaffold is composed of a Polyvinylidene fluoride (PVDF) nanofibrous mat, a Collagen/Polyvinyl Alcohol (PVA) composite loaded with metformin hydrochloride, and polyhydroxybutyrate (PHB) embedded with aceclofenac. The physico-chemical and biochemical characterization of the hybrid scaffold indicated potential efficacy. Electron microscopic studies indicated the porous structure of hybrid polymeric framework (HPF) scaffold which aided significant drug release (metformin and aceclofenac) of 72.2% and 63.9% respectively in 24 h. The hybrid polymeric framework showed swelling of 150-200% to enable drug release along with the efficient exudate absorption that forms the prerequisite for chronic wounds. The HPF scaffold had displayed 93.5% cell viability, 98.7% hemocompatibility, 73.9% in-vitro wound contraction and an improved anti-oxidant activity, that supports the tissue repair in chronic wounds. Thus, the developed hybrid scaffold highlights its potential as an advanced holistic solution for chronic wound management.
Indexed as
Identifiers
40380017What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.